Login to Your Account



BTG's Varisolve Hits Phase III Endpoint; NDA Filing in 2012

By Nuala Moran
Staff Writer

Wednesday, April 25, 2012
LONDON – BTG plc announced positive results in the second U.S. Phase III pivotal trial of its nonsurgical varicose vein treatment Varisolve, to add to positive data from another Phase III that reported at the end of January, and said it will file for FDA approval before the end of 2012.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription